Report
Ogeday Gurbuz
EUR 8.55 For Business Accounts Only

MLP Care (MPARK TI) - In the red despite improvements: Maintain Hold

MPARK’s 2Q19 net loss was slightly worse than our estimate (mostly due to higher minority interest), but significantly worse than RT consensus. Meanwhile, EBITDA was slightly higher than our estimate (mostly due to higher-than-expected depreciation) and significantly higher than RT consensus. Revenue was in line with our estimate but slightly worse than RT consensus. We believe MPARK’s adoption of IFRS 16 standards is the likely cause of the significant deviation in its numbers from those of consensus.

We maintain our HOLD recommendation on MPARK as we do not see significant growth opportunities until a deleveraging can occur and a stronger balance sheet is built up

Provider
Teb Yatirim
Teb Yatirim

TEB Investment equity research analysts and strategist team consists of 8 analysts with an average finance sector experience of 15 years and special focus on international investors.

With our 6 equity research analysts we cover 93 companies across 21 sectors, reflecting 80% of the total market capitalization of all BIST companies and 86% of the BIST100 companies. Our strategy team provides in depth top-down and bottom-up market views with insight on FX and bond markets by publishing sectoral and strategic reports both in English and Turkish.

Analysts
Ogeday Gurbuz

Other Reports from Teb Yatirim

ResearchPool Subscriptions

Get the most out of your insights

Get in touch